T-box transcription factor T (Brachyury) (T)

T-box transcription factor T, commonly known as Brachyury, is a member of the T-box family of transcription factors that plays a critical role in mesoderm formation and cellular differentiation during embryonic development (UniProt P10899). While its expression is minimal in healthy adult tissues, it is frequently overexpressed in a variety of human cancers, particularly chordoma and advanced carcinomas of the lung, breast, and prostate (PubMed: 20538912). Brachyury acts as a key driver of the epithelial-mesenchymal transition (EMT), a phenotypic switch that promotes tumor invasion, metastasis, and resistance to chemotherapy and radiation (PubMed: 24907110). Due to its tumor-specific expression and essential role in progression, it is targeted via immunotherapeutic strategies such as cancer vaccines (e.g., MVA-Brachyury-TRICOM and GI-6301). These vaccines are designed to stimulate the host immune system to generate Brachyury-specific CD8+ and CD4+ T-cells that recognize and eliminate tumor cells expressing the protein (PubMed: 25573381). Clinical studies have shown that targeting Brachyury can induce robust immune responses with manageable toxicity, making it a significant focus for treating metastatic and treatment-resistant malignancies (PubMed: 28213448). The specificity of T-cell recognition ensures that the cytotoxic effect is directed primarily at the malignant cells while sparing normal tissues. Ongoing research continues to evaluate Brachyury-targeted therapies in combination with other immunomodulators to enhance clinical efficacy.

Other names

BrachyuryT-box protein TProtein TTBTT-box transcription factor T

Induction of a specific T-cell mediated immune response against cells expressing the Brachyury protein via therapeutic vaccines that present Brachyury-derived epitopes on MHC class I and II molecules (PubMed: 25573381).